Compare Gilead Sciences, Inc. (GILD) vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.84 (market cap $156.97B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays the higher dividend (2.34%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 0 Days on average.
| GILD | SMFG | |
|---|---|---|
Market Cap | $182.40B | $156.97B |
Volume | 4,469,821 | 1,237,125 |
Sector | Health | Financials |
52-Week High | $155.80 | $27.56 |
52-Week Low | $116.74 | $15.20 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $205.46B | $12.48T |
Dividend Yield | 2.23% | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →
